Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04771611 · ClinicalTrials.gov registry record · Phase 2
COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications
A Phase 2 study of Covid19 and Coronavirus Infection, sponsored by James L. Kirkland, MD, PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT04771611 is a Phase 2 study of Covid19 and Coronavirus Infection that has completed, run by James L. Kirkland, MD, PhD. The registered enrollment target is 55 participants, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04771611, a Phase 2 study of Covid19 and Coronavirus Infection, has completed, sponsored by James L. Kirkland, MD, PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fisetin
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-07-14 |
| Est. Completion | 2022-09-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04771611
The ClinicalTrials.gov registry entry for NCT04771611 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,702-participant average among 94 other Covid19 trials with a reported enrollment target (98% lower). The listed sponsor is James L. Kirkland, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Covid19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04771611 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT04771611 about?
NCT04771611 is a clinical study titled "COVFIS-HOME: COVID-19 Pilot Study of Fisetin to Alleviate Dysfunction and Decrease Complications". The purpose of this study is to test whether Fisetin, a senolytic drug can assist in the reduction of complications in patients with COVID-19 infection.
What is the current status of trial NCT04771611?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2021-07-14. Estimated completion is 2022-09-27.
What conditions does trial NCT04771611 study?
This clinical trial studies the following conditions: Covid19, Coronavirus Infection.
What interventions are being tested in trial NCT04771611?
The interventions under investigation include: Placebo (DRUG), Fisetin (DRUG).
Who is sponsoring clinical trial NCT04771611?
This trial is sponsored by James L. Kirkland, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04771611 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Covid19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imaging Immune Activation in COVID-19
RECRUITING · Phase 2
-
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
RECRUITING · Phase 2
-
Defibrotide for the Treatment of Severe COVID-19
RECRUITING · Phase 2
-
SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial
ACTIVE NOT RECRUITING · Phase 2
-
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.